Indivior Future Growth

Future criteria checks 5/6

Indivior is forecast to grow earnings and revenue by 48.6% and 6.9% per annum respectively. EPS is expected to grow by 46.6% per annum. Return on equity is forecast to be 86% in 3 years.

Key information

48.6%

Earnings growth rate

46.6%

EPS growth rate

Pharmaceuticals earnings growth	16.3%
Revenue growth rate	6.9%
Future return on equity	86.0%
Analyst coverage	Good
Last updated	09 Aug 2024

Recent future growth updates

Recent updates

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Aug 09

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

May 29

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

May 03

Earnings and Revenue Growth Forecasts

LSE:INDV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,358	373	337	423	5
12/31/2025	1,233	260	243	259	7
12/31/2024	1,185	116	312	33	7
6/30/2024	1,147	-141	-279	-227	N/A
3/31/2024	1,124	5	-383	-334	N/A
12/31/2023	1,093	2	-368	-315	N/A
9/30/2023	1,042	-235	-89	-52	N/A
6/30/2023	1,002	-59	-22	-11	N/A
3/31/2023	947	-50	23	35	N/A
12/31/2022	901	-53	-9	-4	N/A
9/30/2022	882	166	176	181	N/A
6/30/2022	838	152	160	145	N/A
3/31/2022	818	166	175	189	N/A
12/31/2021	791	205	339	353	N/A
9/30/2021	753	156	101	115	N/A
6/30/2021	725	139	81	115	N/A
3/31/2021	674	95	39	42	N/A
12/31/2020	647	-148	-197	-193	N/A
9/30/2020	595	-190	-84	-82	N/A
6/30/2020	634	-152	-70	-69	N/A
3/31/2020	700	-95	-131	-130	N/A
12/31/2019	785	134	148	151	N/A
9/30/2019	889	213	217	200	N/A
6/30/2019	935	254	281	275	N/A
3/31/2019	988	248	401	413	N/A
12/31/2018	1,005	275	299	303	N/A
9/30/2018	1,033	106	247	276	N/A
6/30/2018	1,064	67	171	210	N/A
3/31/2018	1,083	71	N/A	260	N/A
12/31/2017	1,093	58	N/A	295	N/A
9/30/2017	1,087	281	N/A	360	N/A
6/30/2017	1,080	81	N/A	409	N/A
3/31/2017	1,065	65	N/A	370	N/A
12/31/2016	1,058	35	N/A	407	N/A
9/30/2016	1,047	-6	N/A	326	N/A
6/30/2016	1,028	191	N/A	283	N/A
3/31/2016	1,021	201	N/A	252	N/A
12/31/2015	1,014	228	N/A	320	N/A
9/30/2015	1,037	268	N/A	300	N/A
6/30/2015	1,058	314	N/A	369	N/A
3/31/2015	1,085	361	N/A	530	N/A
12/31/2014	1,115	403	N/A	440	N/A
9/30/2014	1,147	443	N/A	572	N/A
12/31/2013	1,216	489	N/A	791	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INDV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: INDV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: INDV is expected to become profitable in the next 3 years.

Revenue vs Market: INDV's revenue (6.9% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: INDV's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INDV's Return on Equity is forecast to be very high in 3 years time (86%).

Indivior Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior plc Reconfirms Earnings Guidance for 2024

Recent updates

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior (LON:INDV) Seems To Use Debt Quite Sensibly

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Investor sentiment deteriorated over the past week

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder